Fig. 3
From: Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Pooled prevalence of MSI-H and dMMR among different tumor types. Bar graphs show the prevalence of MSI-H and dMMR in various cancers as summarized by Lorenzi et al. and Lam et al. [93, 94]. Low prevalence of MSI-H in Ewing sarcoma (ES) and wide variation of dMMR between sarcoma subtypes warrants further studies to explore the correlation between MSI-H / dMMR and clinical response to immune checkpoint inhibition. Results from Lorenzi et al. were pooled from various studies. Lam et al. did not evaluate for MSI-H. Asterisk indicates analysis for dMMR was not feasible. ARMS: Alveolar rhabdomyosarcoma; ASPS: Alveolar soft part sarcoma; CRC: Colorectal cancer; CS: Chondrosarcoma; ERMS: Embryonal rhabdomyosarcoma; ES: Ewing sarcoma; LMS: Leiomyosarcoma; MPNST: Malignant peripheral nerve sheath tumor; OGS: Osteosarcoma; PRMS: Pleomorphic rhabdomyosarcoma; SS: Synovial sarcoma. Asterisk indicates analysis for dMMR was not included